Progress is not about how we grow, it is about how we make a difference in lives of others! This is the guiding principle at Yashraj Biotechnology Limited (YBL), a pioneering biotechnology company located in Navi Mumbai, India. The founder members of the company Mr. Arvind Bhanushali, Mr. Bharat Dagha and Dr. Paresh Bhanushali started the company in 1999 and this year the company is celebrating its 20 years of
The company was established with a vision to be the best in the diagnostic field and make diagnostics
affordable and easily available to the common man. Today, YBL is a leading name in the in vitro diagnostic market, supplying high purity Antigens, Antibodies, proteins and enzymes to some of the world’s top 20
From Bio-Medical Waste to Diagnostic Application Products: An Innovative Approach
YBL capitalizes on usefulness of the human biomedical waste generated by the hospitals for diagnostic
purposes by manufacturing Native Antigens (Table 1) which are purified from the effusions of patients
suffering from cancer, renal, and cardiac failures. In addition to diagnostic use, the manufacturing processes at YBL indirectly helps in reducing the environmental pollution due to disposal of human biomedical waste which is a major concern to the hospitals, the regulatory authorities and the citizens.
The Biomedical waste management teams at YBL have created a Pan India network to access Bio-medical fluids for extraction and purification of high quality Native and Recombinant Antigens in a time-effective manner.
State-of-the-Art Research & Development
YBL has a well-equipped Research & Development (R&D) unit in which a wide range of high-quality Antigens (Native and Recombinant), Proteins, Enzymes are manufactured using advanced chromatography systems like AKTA prime plus and AKTA Pure for protein purification.
The Recombinant R&D facility manufactures highly purified proteins and enzymes both with and without tags and by using different expression systems like Bacterial (E. coli), Mammalian (CHO, HeLa, HEK293, MCF7), Bacculovirus (Spodoptera frugiperda) Sf9/Sf21 insect cells and Yeast (Saccharomyces cerevisiae).
Highly specific and high affinity monoclonal and polyclonal Antibodies are developed and characterized by Surface Plasma Resonance (SPR) using Biacore T200 system. These Antibodies are validated by external agencies and certified for use in development of immunoassays like Enzyme-linked Immuno Sorbent Assay (ELISA), Flow Cytometry, Chemiluminescence Assays (CLIA) and Immunohistochemistry (IHC).
YBL products basket contains more than 25 Native and 22 Recombinant Antigens with a purity percentage ranging from 90-99% (To download YBL products booklet please write to firstname.lastname@example.org).
Efficient Production and Rigorous Quality Checks
A seamless transition occurs between the R&D and the production unit for scaling up and mass production of protein. Standard operating procedures are followed to maintain batch to batch consistencies irrespective of capacity (from small to bulk production). The emphasis lies on the maintenance of long-term stability, specificity and purity of the products which is ensured by Quality Control. Rigorous testings are performed on multiple platforms like Roche Cobas e411 & c311 and Siemens Advia Centaur CP & XP analyzers.
Protein quantification and validation is done using ELISA, ECLIA, Immunonephelometry, Immunoturbidimetry and Latex Agglutination, SDS-PAGE, Western Blotting, HPLC, Crossed immunoelectrophoresis (CIE) and Mass-Spectrometry. Real and accelerated stability tests are performed for batch consistency and viral contamination is identified by performing PCR and USFDA approved CLIA techniques. Once the protein quality is confirmed and certified, they are properly labeled and packaged for a timely delivery to the customers worldwide.
Stem Cell & Antibody Phage Display: New Ventures
In the last 2 years, YBL is diversifying its R&D activities to develop IPSCs Stem Cell technology for drug discovery and screening. It has successfully developed methodologies to bio-bank peripheral blood mononuclear cells and erythroblast cell populations from cancer patients and healthy individuals (controls).
In 2018, YBL ventured into production of Recombinant Monoclonal Antibodies using Phage Display for Diagnostic & Research purpose. Currently, both the facilities are in initial stages of development and the products are expected to be available in the market by July 2020.
CSR at YBL: Grants and Awards Sponsorship
Every year YBL donates a percentage of the profit for Corporate Social Responsibility (CSR) initiatives like Healthcare and Education for the welfare of economically weaker section of the society. The amount depends on the profit generated and is decided by the Board. For more details please see http://yashraj.com/csr/
The YBL company’s major activities involve:
Isolation, purification and production of Native and Recombinant proteins;
Development of polyclonal and monoclonal Antibodies against
Production of cell-derived Native Antigens using appropriate cell lines.
Moreover, YBL in collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) sponsors the IFCC-Yashraj Biotechnology Limited Distinguished Clinical Chemist Award & IFCC-Yashraj Biotechnology Limited Distinguished Award for Contributions to Affordable In vitro Diagnostics to recognize researchers who have made significant contributions in this discipline.
Come and join us at Yashraj Biotechnology Limited in our quest to make diagnostics more affordable and accessible!
For any query please write to email@example.com
Twitter handle: @YashrajBio
Facebook: Yashraj Biotechnology Ltd
Certifications:: ISO 9001: 2015 and ISO 13485: 2016